Inkjet-bioAM Open Call

The Inkjet-bioAM Open Call offers funding for projects focusing on Smart Manufacturing of Biomedical Applications using industrial Multi-material Inkjet Processes, intending to improve healthcare. The call is part of the EU's Interregional Innovation Investments Instrument (I3-2024-INV1) and is targeted at consortia of various innovation actors. Eligible applicants include small and medium enterprises (SMEs), research institutions, universities, and other entities from quadruple helix ecosystems.

The funding is structured as a grant, with a total available budget of 540,000 euros for this call. This program emphasizes collaboration, requiring consortia of at least 3-5 partners from different EU member states. The project aims to develop technologies that are commercial-ready, targeting stages from Technology Readiness Levels 6 to 9.

Proposals should align with smart specializations such as green and digital transitions and smart manufacturing. The geographic scope is primarily within EU regions, but specifics are not detailed. The application process is single-stage, concluding with a submission deadline of September 15, 2025, with evaluations based on criteria like innovation potential and technical viability.

Co-funding of 30% is expected from beneficiaries, aligning with standard ERDF rules. The overall project timeline includes a nine-month participation phase, with results reported at the end of this period. Interested parties are directed to the call's official communications for additional information.

The Inkjet-bioAM Open Call is a funding opportunity within the EU's Smart Manufacturing of Biomedical Applications by industrial Multi-material Inkjet Processes for improved Health Care project. The grant agreement number for the overall project is 101161350. The topic is I3-2023-INV1 - 2000-12-31T17:00:00.000Z.

The opening date for submissions is June 16, 2025, at 00:00 (CEST). The deadline for submissions is September 15, 2025, at 17:00 (Brussels time). This is a single-stage submission process.

The expected duration of participation is 9 months. The total funding available for this open call is 540,000.00 €.

The evaluation process will consider the following aspects, each scored with a maximum of 3 points: Quality and innovation potential, Contribution to the value chain of the Inkjet-bioAM project, Utility of the Inkjet-bioAM technologies and technical viability, and Prospective analysis (feasibility and sustainability).

The evaluation timeline is as follows: October 1st to November 30th, 2025, involves evaluation and gathering of additional information. December 1st to December 15th, 2025, involves communication of the decision to participants. January 1st to February 28th, 2026, involves negotiation of the Sub-Grant agreement with relevant partners. March 1st to November 30th, 2026, involves development of the co-creation plan and implementation of the project in consortium with project partners. January 1st to January 30th, 2027, involves submission of the final report and presentation of project results in the final event.

For further information, refer to the open call link: Open Call | inkjet bioAM. Contact opencall@inkjetbioam.com for inquiries.

In summary, this open call is part of the Inkjet-bioAM project, which focuses on smart manufacturing of biomedical applications using industrial multi-material inkjet processes. It seeks proposals that demonstrate quality and innovation, contribute to the project's value chain, utilize Inkjet-bioAM technologies, and are feasible and sustainable. The total funding available is 540,000.00 €, and the project duration is 9 months. The submission window is from June 16, 2025, to September 15, 2025. The evaluation process involves assessing the quality, innovation, contribution, utility, and feasibility of the proposed projects. Successful applicants will then negotiate a sub-grant agreement, develop a co-creation plan, implement the project, and submit a final report.

Eligible Applicant Types: The information provided does not explicitly state the eligible applicant types. However, the mention of "negotiation of the Sub-Grant agreement with relevant partners" and "implementation of the project in consortium with project partners" suggests that the opportunity is open to multiple types of entities that can form a consortium. Further information is needed to determine the specific types of eligible applicants.

Funding Type: The opportunity is a grant, specifically "Cascade funding" as indicated in the provided text. It is also referred to as a "Sub-Grant agreement".

Consortium Requirement: The opportunity requires a consortium, as indicated by the phrases "implementation of the project in consortium with project partners" and "Development of the co-creation plan and implementation of the project in consortium with project partners."

Beneficiary Scope (Geographic Eligibility): The geographic eligibility is not explicitly stated. However, given that it is an EU-funded project, it is likely that the beneficiaries must be from EU member states or associated countries. Further information is needed to confirm the specific geographic eligibility.

Target Sector: The target sector is biomedical applications and smart manufacturing, specifically related to "Smart Manufacturing of Biomedical Applications by industrial Multi-material Inkjet Processes for improved Health Care". This falls under the broader categories of health, manufacturing, and potentially biotech/medtech.

Mentioned Countries: No specific countries are mentioned. The opportunity is an EU-funded project, so it is implied that it is open to entities within the EU.

Project Stage: The project stage appears to be development and implementation, as indicated by the "Development of the co-creation plan and implementation of the project in consortium with project partners." The project is expected to result in a final report and presentation of project results, suggesting it is beyond the initial research phase.

Funding Amount: The total funding available is 540,000.00 €. The funding range for individual projects within the consortium is not specified, but it would be a portion of this total amount.

Application Type: The application type is an open call, as indicated by "Link to the open call: Open Call | inkjet bioAM". The deadline model is single-stage.

Nature of Support: The beneficiaries will receive money in the form of a grant (cascade funding/sub-grant).

Application Stages: The application process appears to be single-stage, as indicated by "Deadline model single-stage". However, there are multiple steps in the overall process, including evaluation, communication of decision, negotiation of the sub-grant agreement, development of the co-creation plan, implementation, and submission of the final report.

Success Rates: The success rates are not mentioned in the provided text.

Co-funding Requirement: The information provided does not explicitly state whether co-funding is required.

Summary:

This opportunity is an open call for cascade funding (sub-grants) under the EU-funded Inkjet-bioAM project, which focuses on Smart Manufacturing of Biomedical Applications by industrial Multi-material Inkjet Processes for improved Health Care. The total funding available is 540,000.00 €. The application deadline is September 15th, 2025. The project requires a consortium of partners to develop a co-creation plan and implement the project. The evaluation criteria include quality and innovation potential, contribution to the value chain of the Inkjet-bioAM project, utility of the Inkjet-bioAM technologies and technical viability, and prospective analysis (feasibility and sustainability). The application process is single-stage, but the overall project involves multiple phases, including evaluation, negotiation of the sub-grant agreement, implementation, and final reporting. The expected duration of participation is 9 months. The geographic eligibility is not explicitly stated but is likely focused on EU member states and associated countries. The project aims to advance the use of inkjet printing technologies in the biomedical field.